首页> 外文OA文献 >Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3 -mutation, localized transformation to EGFR -mutated SCLC, and acquired T790M EGFR -mutation

【2h】

Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3 -mutation, localized transformation to EGFR -mutated SCLC, and acquired T790M EGFR -mutation

机译：用Erlotinib治疗的EGFR外显子19-突变的非小细胞肺癌患者的异质性抗性机制：持久的FGFR3 - 抵抗，局部转化为EGFR - 估计SCLC，并获得T790M EGFR - 抵抗

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Eric Santoni-Rugiu; Morten Grauslund; Linea C. Melchior; Junia C. Costa; Jens B. Sørensen; Edyta M. Urbanska;
展开▼
作者单位

展开▼
年度 2017
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3 -mutation, localized transformation to EGFR -mutated SCLC, and acquired T790M EGFR -mutation [J] . Eric Santoni-Rugiu, Morten Grauslund, Linea C. Melchior, Lung cancer: Journal of the International Association for the Study of Lung Cancer . 2017,第期

机译：EGFR外显子19-突变的非小细胞肺癌患者用Erlotinib处理：持久的FGFR3 - utgute，局部转化为EGFR - 估计SCLC，并获得了T790M EGFR - 抵抗
2. P3.01-007 Heterogeneous Resistance Mechanisms in Rebiopsies from EGFR-Mutated NSCLC: Transformation to SCLC; FGFR3 and T790M Mutations [J] . E. Urbanska, M. Grauslund, L. Melchior, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2017,第11期

机译：P3.01-007 EGFR-突变NSCLC中的refiopsies中的异质电阻机制：转化为SCLC; FGFR3和T790M突变
3. Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations [J] . Lin Yen-Ting, Chen Jin-Shing, Liao Wei-Yu, International Journal of Cancer =: Journal International du Cancer . 2019,第11期

机译：临床结果和次生表皮生长因子受体（EGFR）T790M突变在一线吉非替尼，厄洛替尼和阿凡哚治疗的非小细胞肺癌患者的激活EGFR突变
4. Association between tumor heterogeneity and progression-free survival in non-small cell lung cancer patients with EGFR mutations undergoing tyrosine kinase inhibitors therapy [C] . Jiangdian Song, Di Dong, Yanqi Huang, Annual International Conference of the IEEE Engineering in Medicine and Biology Society . 2016

机译：接受酪氨酸激酶抑制剂治疗的EGFR突变非小细胞肺癌患者肿瘤异质性与无进展生存的关系
5. Design, Construction, and Verification of a LATE-PCR and Lights-On/Lights-Off Probe Assay for Mutation Detection in Exons 18-21 of the EGFR Gene: Implications for Molecular Diagnosis of Non-Small Cell Lung Carcinoma [D] . Tetrault, Shana Augustin 2012

机译：用于EGFR基因外显子18-21突变检测的LATE-PCR和开/关灯探针检测的设计，构建和验证：对非小细胞肺癌的分子诊断意义
6. Osimertinib for advanced non-small cell lung cancer harboring EGFR mutation exon 20 T790M acquired resistant mutation for first- or second-generation EGFR-TKI [O] . Yusuke Okuma, Yukio Hosomi 2017

机译：奥西替尼用于携带EGFR突变外显子20 T790M的晚期非小细胞肺癌第一代或第二代EGFR-TKI的获得性耐药突变
7. P3.01-007 Heterogeneous Resistance Mechanisms in Rebiopsies from EGFR-Mutated NSCLC: Transformation to SCLC; FGFR3 and T790M Mutations [O] . E. Urbanska, M. Grauslund, L. Melchior, 2017

机译：P3.01-007 EGFR-突变NSCLC中的refiopsies中的异质电阻机制：转化为SCLC; FGFR3和T790M突变

Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3 -mutation, localized transformation to EGFR -mutated SCLC, and acquired T790M EGFR -mutation

著录项

引文网络

相似文献

相关主题

期刊订阅